A missense point mutation in nerve growth factor (NGFR100W) results in selective peripheral sensory neuropathy
- PMID: 32693191
- PMCID: PMC12327444
- DOI: 10.1016/j.pneurobio.2020.101886
A missense point mutation in nerve growth factor (NGFR100W) results in selective peripheral sensory neuropathy
Abstract
The R100W mutation in nerve growth factor is associated with hereditary sensory autonomic neuropathy V in a Swedish family. These patients develop severe loss of perception to deep pain but with apparently normal cognitive functions. To better understand the disease mechanism, we examined a knockin mouse model of HSAN V. The homozygous mice showed significant structural deficits in intra-epidermal nerve fibers (IENFs) at birth. These mice had a total loss of pain perception at ∼2 months of age and often failed to survive to adulthood. Heterozygous mutant mice developed a progressive degeneration of small sensory fibers both behaviorally and functionally: they showed a progressive loss of IENFs starting at the age of 9 months accompanied with progressive loss of perception to painful stimuli such as noxious temperature. Quantitative analysis of lumbar 4/5 dorsal root ganglia revealed a significant reduction in small size neurons, while analysis of sciatic nerve fibers revealed the heterozygous mutant mice had no reduction in myelinated nerve fibers. Significantly, the amount of NGF secreted from mouse embryonic fibroblasts were reduced from both heterozygous and homozygous mice compared to their wild-type littermates. Interestingly, the heterozygous mice showed no apparent structural alteration in the brain: neither the anterior cingulate cortex nor the medial septum including NGF-dependent basal forebrain cholinergic neurons. Accordingly, these animals did not develop appreciable deficits in tests for brain function. Our study has thus demonstrated that the NGFR100W mutation likely affects the structure and function of peripheral sensory neurons.
Keywords: Cognition; Dorsal root ganglion; Hereditary sensory autonomic neuropathy V; Intraepidermal nerve fiber; Knockin mouse model; Nerve growth factor; Nociception; Pain; TrkA; p75 neutrophic factor receptor.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures








References
-
- Apfel SC, 2002. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int. Rev. Neurobiol. 50, 393–413. - PubMed
-
- Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, 1998. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 51, 695–702. - PubMed
-
- Blesch A, Tuszynski M, 1995. Ex vivo gene therapy for Alzheimer’s disease and spinal cord injury. Clin. Neurosci. 3, 268–274. - PubMed
-
- Bothwell M, 1995. Functional interactions of neurotrophins and neurotrophin receptors. Annu. Rev. Neurosci. 18, 223–253. - PubMed
-
- Capsoni S, 2014. From genes to pain: nerve growth factor and hereditary sensory and autonomic neuropathy type V. Eur. J. Neurosci. 39, 392–400. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials